

MBO at SEP provides capital to accelerate growth and expansion

The Management Team of Speciality European Pharma Limited (SEP), today announce their acquisition of the Company from its venture capital shareholders, with the backing of Juno Pharmaceuticals Inc. (Juno), an international specialty pharmaceutical company and leading life science investor.

Headquartered in the UK, SEP is a speciality pharmaceutical and medical devices group that focuses on meeting the needs of the specialist physician. The Company was founded in 2006 and has grown rapidly over the past five years, with a commercial presence in much of Europe and a desire to grow beyond. The MBO provides the Company with the opportunity to not only continue its growth strategy with the existing products but to also invest for the long-term in the untapped potential in its proprietary development portfolio. Near term objectives for this investment include United States approval for Bulkamid, the group's urethral bulking agent, and EU approval of Arthrosamid, the group's synovial implant for osteoarthritis.

Commenting on the MBO, Patrick Banks, Chief Executive Officer of SEP, said:

"SEP is at an exciting juncture in its development. Having already established a strong commercial footprint in the EU, the Company acquired Contura, a medical devices business, in April 2013. This acquisition has proved a great success and with the increased financial strength that has come from substantial revenue growth and the backing that now comes from Juno, the group is well placed to make the significant investments required to deliver its true potential."

Commenting on the MBO, Ian Jacobson, Chief Executive Officer of Juno, said:

"We are very excited about our acquisition of SEP and partnership with its management team. SEP's niche product portfolio and strategic focus aligns perfectly with Juno's corporate mission and we look forward to building on SEP's impressive track record of growth. We view SEP as a company that has only begun to realise its considerable potential and we are confident that in partnership with its existing management team, we can build it into one of Europe's leading pharmaceutical and medical device companies."

-ENDS-

For further information please contact:

SEP
Patrick Banks, Chief Executive Officer

Tel: +44 (0)20 7421 7400

About SEP

1. SEP is the parent company of a group which specialises in the distribution and sale of pharmaceutical products and medical devices, focused primarily upon the fields of urology and urogynaecology. Its marketed products are:

Bulkamid®
Aquamid®
Mitem®
Cystistat®
Regurin® and Regurin® XL

The Company was founded in 2006 and has built an experienced and accomplished management team. SEP has established a sales and marketing infrastructure in the leading European markets. It has offices in the UK, Denmark, Germany and France, with specialist Distributor partners across the world.

The Group, currently, employs some 45 staff throughout Europe.

2. SEP also has portfolio of development/approval opportunities for new products derived from its proprietary polyacrylamide gel technology. These opportunities include:
 - Bulkamid® approval in the United States
 - Arthrosamid®, a synovial implant for osteoarthritis, currently undergoing regulatory approval in the EU
 - Rectamid® for faecal incontinence in clinical development

About Juno

Juno Pharmaceuticals Inc. is an international specialty pharmaceutical company with operations in Canada, Australia, South Africa and Europe. Juno works closely with its portfolio companies around the world to identify and in-license value-added and differentiated specialty generics, brands and medical devices to ensure that customers and patient groups alike within their respective territories have access to the medicines they require.